In the US and Nordic countries 14 highrisk (hr) human papillomavirus (HPV) types cause 5 and 10 percent of cancers in males and females, respectively. Half of these cancers are caused by HPV type 16. 1 Hr-HPVs are acquired by sexual contact, and one third of young adults are hr-HPV DNA positive, i.e., transmitting HPV. 2 Ninety percent of cervical hr-HPV infections heal in 1.5 y but if persistent can develop into cervical cancer (CC). The world age-standardized incidence of CC was 14.5/100,000 in 2008, and in a number of countries is increasing together with the incidence of hr-HPV associated oropharyngeal and other anogenital cancers. Developing countries can never tackle hr-HPV disease burden by screening/treatment. Primary prevention by vaccination is the only hope.
Thirty years ago zurHausen's group discovered HPV16 in cervical cancer, 3 20 years ago HPV16 virus-like particles (VLPs) were developed, 4 and 10 years ago first results on the immunogenicity and efficacy of the HPV16 VLP vaccine were published proving the principle. 5 Recently, we showed in a four-year clinical Phase III trial that HPV16/18 vaccine prevents 93.2% of all CIN3 + lesions in baseline naive adolescents. 6 The lower 95% confidence limit of 80% indicates that this highly efficacious vaccine provides better protection against CC than the best Pap-screening programs. Partial cross-protection against The basis for the cross-protection may be comparable conformational structure close to the major neutralizing VLP epitopes that are recognized by HPV16.V5 and HPV18.J4 antibodies in the FG and HI loops of the corresponding viral pentamers. 8 Due to this conformational correspondence, the cross-reactive sites may reside or be recognizable in the vicinity of amino acids 261-280 and 397-416 8, 9 ( Fig. 1) . These, so far hypothetical, epitopes might correspond to their monoclonal antibody recognized counterparts in HPV16 L1 and HPV31/33/35 L1, and in HPV18 L1 and HPV45 L1 as suggested by the cross-reactivity of HPV16.J4 and HPV18.Q2 antibodies. 8, 9 Mechanisms of cross-protection against HPV51 remain elusive.
Sound efficacy of prophylactic HPV vaccination

Basics and implications
Possibly due to the AS04 adjuvant, HPV-16/18 vaccine induced antibodies are detectable > 8 y post vaccination. Very long-term stability of the cross-neutralizing human antibodies, and whether boostering is needed at all remain to be seen.
HPV vaccination coverage is at best 80% but usually much lower. A form of denialism, clustering of non-attendance to vaccination and screening, threatens to jeopardize public health programs aiming to control HPV disease burden. It might also give rise (by creating ecological niche) to type-replacement following On the contrary, the incidence of clade A9 infections was decreased in HPV16/18 vaccinated as compared with hepatitis A vaccinated women. The full impact of herd immunity on hr-HPV epidemiology will, however, be assessed in an ongoing community-randomized trial in which 12-15 y old girls and boys received the HPV16/18 vaccine (11 communities), girls only received the HPV16/18 vaccine (11 communities), or girls and boys received hepatitis B vaccine (11 communities). 10 The yet-to-be-verified most efficient vaccination strategy will hopefully guide decision makers. 
